Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDTX NYSE:MRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTXCidara Therapeutics$221.38+0.0%$220.96$18.51▼$221.42$6.96B1.52928,762 shs2.69 million shsMRKMerck & Co., Inc.$127.47-0.1%$120.11$76.66▼$131.74$314.90B0.199.90 million shs13.47 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTXCidara Therapeutics0.00%0.00%0.00%0.00%+323.61%MRKMerck & Co., Inc.0.00%+3.03%+11.78%+7.12%+54.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTXCidara Therapeutics$221.38+0.0%$220.96$18.51▼$221.42$6.96B1.52928,762 shs2.69 million shsMRKMerck & Co., Inc.$127.47-0.1%$120.11$76.66▼$131.74$314.90B0.199.90 million shs13.47 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTXCidara Therapeutics0.00%0.00%0.00%0.00%+323.61%MRKMerck & Co., Inc.0.00%+3.03%+11.78%+7.12%+54.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDTXCidara Therapeutics 2.30Hold$169.88-23.27% DownsideMRKMerck & Co., Inc. 2.70Moderate Buy$133.945.08% UpsideCurrent Analyst Ratings BreakdownLatest MRK and CDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026MRKMerck & Co., Inc. JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$135.00 ➝ $140.007/13/2026MRKMerck & Co., Inc. BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$135.00 ➝ $142.007/13/2026MRKMerck & Co., Inc. GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $145.007/9/2026MRKMerck & Co., Inc. Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$112.00 ➝ $113.007/8/2026MRKMerck & Co., Inc. Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$142.007/8/2026MRKMerck & Co., Inc. Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$145.00 ➝ $150.007/6/2026MRKMerck & Co., Inc. Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$120.006/30/2026MRKMerck & Co., Inc. Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$130.00 ➝ $141.006/30/2026MRKMerck & Co., Inc. ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Outperform$136.00 ➝ $155.006/24/2026MRKMerck & Co., Inc. CICC ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$138.00(Data available from 7/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDTXCidara TherapeuticsN/AN/AN/AN/A$14.92 per shareN/AMRKMerck & Co., Inc.$65.01B4.84$11.42 per share11.16$21.22 per share6.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDTXCidara Therapeutics-$169.83M-$11.78N/AN/AN/AN/A-45.52%-38.31%N/AMRKMerck & Co., Inc.$18.25B$3.5535.9113.115.0413.59%27.55%10.73%8/4/2026 (Estimated)Latest MRK and CDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026MRKMerck & Co., Inc.-$0.26N/AN/AN/A$16.40 billionN/A4/30/2026Q1 2026MRKMerck & Co., Inc.-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCDTXCidara TherapeuticsN/AN/AN/AN/AN/AMRKMerck & Co., Inc.$3.402.67%+5.75%95.77%14 YearsLatest MRK and CDTX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/26/2026MRKMerck & Co., Inc.quarterly$0.852.96%6/15/20266/15/20267/8/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDTXCidara TherapeuticsN/A4.624.62MRKMerck & Co., Inc.1.021.301.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDTXCidara Therapeutics35.82%MRKMerck & Co., Inc.76.07%Insider OwnershipCompanyInsider OwnershipCDTXCidara Therapeutics3.89%MRKMerck & Co., Inc.0.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDTXCidara Therapeutics9031.44 million30.22 millionNo DataMRKMerck & Co., Inc.75,0002.47 billion2.47 billionOptionableMRK and CDTX HeadlinesRecent News About These CompaniesMerck (MRK) Wins FDA Approval For First Oral PCSK9 Cholesterol DrugJuly 19 at 1:34 PM | finance.yahoo.comLittle House Capital LLC Purchases 11,861 Shares of Merck & Co., Inc. $MRKJuly 19 at 6:23 AM | marketbeat.comSEB Asset Management AB Takes $197.55 Million Position in Merck & Co., Inc. $MRKJuly 19 at 6:15 AM | marketbeat.comSwiss National Bank Acquires 440,700 Shares of Merck & Co., Inc. $MRKJuly 19 at 6:07 AM | marketbeat.comMerck & Co., Inc. $MRK Stake Cut by Mediolanum International Funds LtdJuly 19 at 5:52 AM | marketbeat.comJennison Associates LLC Has $751.73 Million Stock Position in Merck & Co., Inc. $MRKJuly 19 at 5:35 AM | marketbeat.comDorsey Wright & Associates Makes New Investment in Merck & Co., Inc. $MRKJuly 19 at 4:16 AM | marketbeat.comFSA Advisors Inc. Decreases Stock Position in Merck & Co., Inc. $MRKJuly 19 at 4:07 AM | marketbeat.comAssetmark Inc. Acquires 57,422 Shares of Merck & Co., Inc. $MRKJuly 19 at 3:12 AM | marketbeat.comHeartland Bank & Trust Co Buys 8,547 Shares of Merck & Co., Inc. $MRKJuly 18 at 5:59 AM | marketbeat.comForty three Eighteen Advisors LLC Takes $2.63 Million Position in Merck & Co., Inc. $MRKJuly 18 at 5:35 AM | marketbeat.comIndependent Financial Group LLC Purchases Shares of 37,402 Merck & Co., Inc. $MRKJuly 18 at 5:19 AM | marketbeat.comHillsdale Investment Management Inc. Trims Stock Holdings in Merck & Co., Inc. $MRKJuly 18 at 4:55 AM | marketbeat.comMerck & Co., Inc. $MRK Shares Sold by California Public Employees Retirement SystemJuly 18 at 4:23 AM | marketbeat.comBessemer Group Inc. Decreases Stock Position in Merck & Co., Inc. $MRKJuly 18 at 3:56 AM | marketbeat.comAtlas Wealth LLC Purchases Shares of 314,776 Merck & Co., Inc. $MRKJuly 18 at 3:19 AM | marketbeat.comAllspring Global Investments Holdings LLC Has $81.27 Million Stake in Merck & Co., Inc. $MRKJuly 18 at 3:06 AM | marketbeat.comMerck: 'Strong Buy' Lipfendra FDA First And Continued Oncology ExpansionsJuly 17 at 4:00 PM | seekingalpha.comMRK Stock Jumps on FDA Nod for Cholesterol-Lowering PillJuly 17 at 1:51 PM | zacks.comThe First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?July 17 at 11:05 AM | 247wallst.comMSD wins FDA approval for cholesterol pill to help plug Keytruda voidJuly 17 at 10:45 AM | pharmaceutical-technology.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRK and CDTX Company DescriptionsCidara Therapeutics NASDAQ:CDTXCidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Merck & Co., Inc. NYSE:MRK$127.47 -0.16 (-0.12%) Closing price 07/17/2026 03:59 PM EasternExtended Trading$127.54 +0.07 (+0.06%) As of 07/17/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/13- 07/17 Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Wall Street Suddenly Sees SpaceX as an AI Company Shopify's Quiet AI Strategy Could Be Its Biggest Advantage Yet TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth Why Intuitive Surgical’s Strong Quarter Still Spooked Investors Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
